LivingGLP1
parallel randomized trial

S003135

Overweight or obesity without diabetes (adults)S003135

Design

Randomized
83
Start year
2022
Treatment
12 weeks, follow-up 26 weeks
Countries
China (3 sites)
Sponsor
Adfontes (Ningbo) Co., Ltd. (mixed)
Eligibility
age 18 to 60; BMI 24 or more; no diabetes

Conduct and analysis

Blinding
open label
Sequence generation
computer
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
completers
Missing data
completers only

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Semaglutide 1.0 mg subcutaneous once weekly
Semaglutide (G group)
lifestyle: not reported343030
A2Lifestyle intervention (randomized arm)
High fibre diet (W group)
lifestyle: standard493939

Results

10 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Percent body weight change (2 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
12A1percent change-5.74 percent-7.62 to -3.8530not stated; completers; R0004305:Results
12A2percent change-5.06 percent-6.19 to -3.9439not stated; completers; R0004305:Results
All cause mortality (2 lines; O20)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 34not stated; randomized; R0004305:Results
A2events0 / 49not stated; randomized; R0004305:Results
Hospitalization for heart failure (2 lines; O23)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 34not stated; randomized; R0004305:Results
A2events0 / 49not stated; randomized; R0004305:Results
Serious adverse events (2 lines; O25)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 34not stated; randomized; R0004305:Results
A2events0 / 49not stated; randomized; R0004305:Results
Death by suicide (2 lines; O35B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 34not stated; randomized; R0004305:Results
A2events0 / 49not stated; randomized; R0004305:Results